Genovis AB
5GV
Company Profile
Business description
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
Contact
Kavlinge
Box 4
LundSE-24421
SWET: +46 46101230
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
36
Stocks News & Analysis
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
stocks
12 picks for an income portfolio - Q1 2026 update
Passive income growth continues to exceed my target.
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,174.10 | 12.00 | 0.13% |
| CAC 40 | 8,331.05 | 94.08 | -1.12% |
| DAX 40 | 24,417.80 | 284.44 | -1.15% |
| Dow JONES (US) | 49,401.44 | 45.99 | -0.09% |
| FTSE 100 | 10,609.08 | 58.55 | -0.55% |
| HKSE | 26,361.07 | 200.74 | 0.77% |
| NASDAQ | 24,388.86 | 79.62 | -0.33% |
| Nikkei 225 | 58,824.89 | 348.99 | 0.60% |
| NZX 50 Index | 12,915.45 | 9.78 | 0.08% |
| S&P 500 | 7,107.82 | 18.24 | -0.26% |
| S&P/ASX 200 | 8,953.30 | 13.60 | 0.15% |
| SSE Composite Index | 4,082.13 | 30.70 | 0.76% |